The Cancer Letter
The Cancer Letter
The Cancer Letter, an independent weekly news publication, has been the leading source for information on the issues that shape oncology since 1973.With a dedicated audience of oncology’s leaders, The Cancer Letter stays on top of breaking news and advances in oncology, providing authoritative, award-winning coverage of the development of cancer therapies, drug regulation, legislation, cancer research funding, health care finance, and public health. This weekly podcast features interviews, discussions, and more to dig deep into the issues that shape oncology.
Be sure to visit the podcast's website and support the creator: cancerletter.com
Author
The Cancer Letter
Category
Podcast website
Latest episode
Nov 18, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Brawley: ACS prostate cancer screening guideline should say no to “mass screening” 18.11.2026 24:58
On Nov. 12, the American Cancer Society published strengthened prostate cancer screening guidelines, advising routine, age-based screening for all men over fifty and men at high risk over age 45. The strengthened recommendation comes after 30 years of advising men to discuss prostate-specific antigen, or PSA, testing, with a physician and weigh the potential benefits and harms, rather than treat...
With the U.S. measles elimination status in jeopardy, the outbreak’s epicenter sees little urgency 11.11.2026 30:30
The United States is projected to lose its measles elimination status, marking a troubling reversal after more than two decades in which the virus was no longer considered endemic. At the center of the outbreak is Pennsylvania, particularly Lancaster County, where nearly 500 of the state’s 1,500 cases have been reported. The outbreak is concentrated in the largely unvaccinated Amish and Plain comm...
Cercek: “The majority of patients in AZUR-1 in a global study were able to avoid all of standard of care” 04.11.2026 39:21
On Oct. 19, FDA granted an accelerated approval to dostarlimab-gxly (Jemperli) for the treatment of patients with previously untreated stage 2 or stage 3 rectal cancer that is mismatch repair deficient or microsatellite instability–high, as determined by an FDA-authorized test. In this episode of The Cancer Letter Podcast, Andrea Cercek, PI for AZUR-1 and section head of colorectal cancer at Memo...
Cancer breakthroughs hit the clinic, cancer policy hits the ballot box 28.10.2026 17:25
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter , and Jacquelyn Cobb, managing editor, discuss promising developments in cancer research and the growing prominence of cancer as an election issue in Iowa. Jaqcuelyn’s conversation with Kevan Shokat, the pioneering chemist whose work helped transform the once undruggable KRAS protein into a ther...
As USPSTF falters and FDA ignores clinical benefit, “the idea that screening is always good is probably gaining traction right now” 21.10.2026 27:32
With the pope’s lung cancer diagnosis jumpstarting conversations about lung cancer screening, and the constant buzz surrounding multi-cancer detection tests, evidence-based evaluation of screening tests is more important than ever, Paul Goldberg, editor and publisher of The Cancer Letter , and Jacquelyn Cobb, managing editor, discussed in this episode of The Cancer Letter Podcast. “This idea that...
The Directors: VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs 16.10.2026 58:48
As the Galleri test is advancing toward becoming the first multi-cancer detection test to secure FDA approval, cancer care providers are coming up with strategies for using these tests responsibly. How will cancer centers counsel patients who walk through the doors with MCD test results? Under what circumstances can cancer physicians rely on this technology? What role will they play in determinin...
As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns” 14.10.2026 25:57
As the oncology community waits with bated breath for a possible FDA approval of GRAIL’s Galleri test, NCI Director Anthony Letai has a lot to say about multi-cancer detection tests—particularly Galleri. Letai spoke at a National Comprehensive Cancer Network policy summit on screening and prevention last week on Oct. 6. “It’s very important when we consider screening studies that we don’t, in our...
Anthony Letai reflects on Year One as NCI Director: “The NCI is in business” 07.10.2026 57:45
“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. Letai recapped his first year as NCI director in conversation with Paul Goldberg, editor and publisher of The Cancer Letter , and laid out his priorities for the year ahead. In the conversation, Letai discusses his goal of calming un...
The Galleri MCD vote: What FDA asked its advisors to ignore 30.09.2026 47:24
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter , Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection...
The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it 25.09.2026 59:47
What should a cancer center look like in an era of AI, genomics, complex patient populations, rising costs, and declining public trust in science? Two directors—both pursuing NCI designations, and serving contiguous Gulf Coast catchment areas—offer profound thoughts on the matter of building a modern cancer center. Raghu Kalluri, senior vice president, executive director, and chief scientific off...
36 months to live, 29 months to wait. Why is Congress withholding lifesaving benefits from breast cancer patients? 23.09.2026 17:06
In this episode of The Cancer Letter Podcast, Fran Visco, president of the National Breast Cancer Coalition, and Jacquelyn Cobb, managing editor of The Cancer Letter , discuss the Metastatic Breast Cancer Act , bipartisan legislation that would eliminate the waiting periods for Social Security Disability Insurance and Medicare for eligible people with metastatic breast cancer. “We realized a numb...
9/11, mRNA, musical chairs—and an assassination attempt 16.09.2026 32:04
This week’s oncology headlines run the gamut—from a discussion on the long-term consequences of 9/11 on lung cancer incidence, to the promise—and limits—of cutting edge mRNA science, to major institutional leadership changes, and even the intersection of cancer and war. In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher with The Cancer Letter, and Jacquelyn Cobb, ma...
As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer 09.09.2026 38:30
Last month, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. In this week’s episode of In the Headlines, Jacquelyn Cobb, associate editor with The Cancer Letter , speaks wi...
Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field 02.09.2026 24:52
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval was much anticipated by patients and clinicians alike, ever since the dramatic results of the RASo...
Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system” 26.08.2026 28:03
On July 21, President Donald Trump announced his latest set of sweeping tariffs on the pharmaceutical industry: a 200% levy on imported generic drugs by the year 2029. Trump imposed tariffs on branded drugs in April, which were met with concern about increased drug costs and decreased U.S. competitiveness in the global drug development market. However, a more dire concern—a familiar one—is arisin...
Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.” 19.08.2026 32:52
In last week’s issue of The Cancer Letter , Raja Flores wrote a guest editorial explaining how he, with his expertise in thoracic surgery, took issue with a nuance in a recent Keytruda commercial. In this week’s episode of In the Headlines, Flores spoke with Paul Goldberg, editor and publisher of The Cancer Letter , to explain how his deep dive into the issue led him to discover a broader issue i...
What happened at FDA? Replimune approval raises questions 12.08.2026 34:43
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy. The approval and the CTGTAC decision f...
The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access 07.08.2026 55:51
New pressures notwithstanding, being a cancer center director is still a dream job, two of the nation’s newest cancer center directors say. In their first weeks in the top jobs at their institutions, Dartmouth’s Roy Herbst and the University of Cincinnati’s David Gius told us how the director’s job comes with an opportunity to imbue the center’s programs with a new energy and explore new direction...
Pour a Scotch, we’re talking clinical trials and prediction markets 05.08.2026 29:53
In last week’s issue of The Cancer Letter , the cover story featured coverage of Kalshi, an online prediction market exchange, launching a pilot program in which one can place bets on both outcomes of trials and FDA decisions. In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher with The Cancer Letter , and Jacquelyn Cobb, associate editor, discuss the Kalshi’s entran...
Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there? 29.07.2026 27:00
Last week, the Pentagon posted a video on X announcing they will be mandating testosterone screening for troops in the military aged 30 and above. If they test low, they will be offered voluntary testosterone replacement therapy. At the same time, FDA has announced it will be loosening safety warnings on the labels for testosterone replacement therapy. The primary evidence base to guide that decis...
How will FDA regulate psychedelics? 22.07.2026 27:00
FDA has been taking a look at psychedelics as a potential treatment for psychiatric and substance abuse disorders, recently publishing a final guidance for drug sponsors conducting clinical trials of psychedelics, including psilocybin, LSD, and MDMA. “This is of interest to psycho-oncologists that have been looking into this question for at least two decades around cancer-related anxiety, depress...
Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way 17.07.2026 1:08:37
The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace. The solution: Speed up clinical trial enrollment by using AI to reduce costs and eliminate bureaucratic red tape. Tasks that ordinarily require hours of manual work for each patient in a single study can now be completed for 100,000 patients in a...
Did peer review fail? Nature Medicine’s chronotherapy paper retraction raises questions 15.07.2026 32:42
The cover story in last week’s issue of The Cancer Letter featured a retraction of a Nature Medicine paper demonstrating that giving patients immunochemotherapy before 3:00 p.m. led to massive improvements in overall survival and progression-free survival. In this week's episode of The Cancer Letter Podcast, editor and publisher Paul Goldberg, and associate editor Jacquelyn Cobb revisit the hi...
A new diagnostic lens—and a lasting scientific legacy 08.07.2026 23:33
In this week's episode of The Cancer Letter Podcast, editor and publisher Paul Goldberg, and associate editor Jacquelyn Cobb revisit two of last week’s most-read stories: the growing recognition that early-onset colorectal cancer requires a new diagnostic mindset, and the life and legacy of Maura Gillison, the scientist whose discovery that most head and neck cancers are driven by HPV transfor...
Breaking down Operation Trailblazer: Rolling INDs, outside expert submission help, and one-trial requirement 01.07.2026 22:48
In this week’s episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter , and Sara Willa Ernst, reporter, break down HHS’ latest vision for the future: Operation Trailblazer. The report is titled: “HHS Roadmap to Maintaining U.S. Leadership in Early Clinical Research and Development.” “The U.S. is apparently losing its leadership in INDs and early phase resea...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.